Wilson's disease

scrapheap
Biotech

AZ licenses discarded rare disease drug to Monopar Therapeutics

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline, licensing Wilson disease candidate ALXN-1840.
Kevin Dunleavy Oct 24, 2024 2:54pm
An illustration of a white strand of DNA which lies horizontally across an image

Ultragenyx tweaks gene therapy dosing to dial up efficacy

Oct 4, 2024 8:46am
Pascal Soriot

AstraZeneca dumps $855M, near-approval rare disease drug

Apr 27, 2023 6:30am